Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 6/20 | 0.62 |
| ▸ | CPT2 | P23786 | 3/20 | 0.62 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556431 | 0.92 | LMNA (0.58) | CPT1ACPT2CPT1BLMNAHPGD | |
| SCHEMBL2825347 | 0.92 | LMNA (0.59) | CPT1ACPT2CPT1BLMNAHPGD | |
| SCHEMBL2827310 | 0.89 | CPT1A (0.79) | CPT1ACPT2CPT1BLMNAHPGD | |
| SCHEMBL2824229 | 0.88 | CPT1A (0.79) | CPT1ACPT2CPT1BALDH1A1KMT2A | |
| SCHEMBL2828881 | 0.87 | CPT1A (0.65) | CPT1ACPT2CPT1BLMNAHPGD | |
| SCHEMBL2825880 | 0.87 | CPT1A (0.69) | CPT1ACPT2CPT1BLMNAHPGD | |
| SCHEMBL12971607 | 0.85 | LMNA (0.79) | CPT1ACPT1BLMNAHPGDALDH1A1 | |
| SCHEMBL2825246 | 0.83 | CPT2 (0.72) | CPT1ACPT2CPT1BLMNAALDH1A1 | |
| SCHEMBL2825285 | 0.82 | LMNA (0.62) | CPT1ACPT2CPT1BLMNAALDH1A1 | |
| SCHEMBL2825316 | 0.81 | LMNA (0.72) | CPT1ACPT2CPT1BLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | disclosed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885CPT1B 2/4885 |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885CPT1B 2/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885CPT1B 2/4885 |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.